World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
49516
World Ranking
7545
National Ranking
3937

Overview

Fernando Cabanillas is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with a specific focus on oncology, pathology, infectious diseases, and immunology.

The scientist's work covers several subfields, including:

  • Pathology and Forensic Medicine
  • Oncology
  • Immunology
  • Infectious Diseases
  • Neurology

Central topics in their research include:

  • Lymphoma Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cutaneous lymphoproliferative disorders research
  • T-cell and Retrovirus Studies

Among the frequently encountered publication venues for Fernando Cabanillas are:

  • Hematological Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • The Lancet

Frequent coauthors collaborating with this researcher include:

  • Marek Trněný
  • Davide Rossi
  • Kensei Tobinai
  • Richard Tsang
  • Jürgen Westermann

Notable recent papers authored or coauthored by Fernando Cabanillas are:

  • "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," 2023, Journal of Clinical Oncology
  • "Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma," 2024, Journal of Clinical Oncology
  • "Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19," 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • "Home-based management of COVID-19 by identification of low-risk features," 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • "Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone," 2020, Blood

Best Publications

  • A predictive model for aggressive non-Hodgkin's lymphoma

    M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage

  • Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    B D Cheson;S J Horning;B Coiffier;M A Shipp

  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    P McLaughlin;A J Grillo-López;B K Link;R Levy

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Non-Hodgkin's Lymphoma in 90 Homosexual Men: Relation to Generalized Lymphadenopathy and the Acquired Immunodeficiency Syndrome

    John L. Ziegler;Jay A. Beckstead;Paul A. Volberding;Donald I. Abrams

  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

    T. Philip;James Olen Armitage;G. Spitzer;F. Chauvin

  • Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

    WS Velasquez;F Cabanillas;P Salvador;P McLaughlin

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

    Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • ESHAP--an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-year Follow-Up Study

    W. S. Velasquez;P. McLaughlin;Susan L Tucker;Fredrick B Hagemeister

  • Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification

    Ming Sheng Lee;Kun Sang Chang;Fernando Cabanillas;Emil J. Freireich

  • The Clinical Behavior of Localized and Multicentric Castleman Disease

    Juan Herrada;Fernando Cabanillas;Lawrence Rice;John Manning

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • IMVP-16: An Effective Regimen for Patients With Lymphoma Who Have Relapsed After Initial Combination Chemotherapy

    Fernando Cabanillas;Fredrick B. Hagemeister;Gerald P. Bodey;Emil J. Freireich

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

  • Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Jorge Cortes;Susan O'Brien;Sherry Pierce

Frequent Co-Authors

Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
James D. Cox
James D. Cox The University of Texas MD Anderson Cancer Center
Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Susan L. Tucker
Susan L. Tucker The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but exploring alternative pathways or looking to branch out in the healthcare field? There are several online degrees and fast-track programs that offer flexibility and quicker entry into rewarding healthcare careers.

For those who want to start working in patient care sooner, fast track lpn programs online can help you become a Licensed Practical Nurse in less time than traditional routes. If you already have a nursing background and wish to specialize in mental health, the fastest psychiatric nurse practitioner program options online are worth considering. These programs prepare you for advanced roles with greater responsibility and earning potential.

Not all health professions require direct patient care. If you’re interested in the administrative side of healthcare, you can explore the cheapest online health science degree for entry-level administration or focus on leadership roles by considering the cheapest mha online programs for your graduate studies.

These options provide cost-effective and accelerated alternatives for students seeking flexibility or a nontraditional route into the healthcare sector.

Best Scientists Citing Fernando Cabanillas

Trending Scientists

Recently Published Articles